Therapeutic monoclonal antibodies and related products have steadily grown to become the dominant product class within the biopharmaceutical market. Production of antibodies requires special precautions to ensure safety and efficacy of the product. In particular, minimizing antibody product heterogeneity is crucial as drug substance variants may impair the activity, efficacy, safety and pharmacokinetic properties of an antibody, consequently resulting in the failure of a product in pre-clinical and clinical development. This review will cover the manufacturing and formulation challenges and advances of therapeutic monoclonal antibodies, with a focus on improved processes to minimize variants and ensure batch-to-batch consistency. Processes put in place by regulatory agencies such as Quality-by-Design (QbD) and current Good Manufacturing Practices (cGMP) will be reviewed, and how their implementation has aided drug development in pharmaceutical companies. Advances in formulation and considerations on the intended use of a therapeutic antibody, including route of administration and patient compliance, will be discussed.